Urinary proteome and systolic blood pressure as predictors of 5-year cardiovascular and cardiac outcomes in a general population

Hypertension

Volumn 66, Issue 1, 2015, Pages 52-60

  Zhang, Zhen Yu ^a   Thijs, Lutgarde ^a   Petit, Thibault ^a   Gu, Yu Mei ^a   Jacobs, Lotte ^a   Yang, Wen Yi ^a   Liu, Yan Ping ^a   Koeck, Thomas ^c   Zürbig, Petra ^c   Jin, Yu ^a   Verhamme, Peter ^b   Voigt, Jens Uwe ^b   Kuznetsova, Tatiana ^a   Mischak, Harald ^c,d   Staessen, Jan A ^a,e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

biomarker; cardiovascular disease; morbidity; mortality; proteomics

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIURETIC AGENT; GLUCOSE; PROTEOME; VASODILATOR AGENT; CHOLESTEROL; PEPTIDE;

ACCURACY; ADULT; AGE DISTRIBUTION; ARTICLE; CAPILLARY ELECTROPHORESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; URINALYSIS; BELGIUM; BLOOD; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS; FOLLOW UP; MASS SPECTROMETRY; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SENSITIVITY AND SPECIFICITY; SURVIVAL; SYSTOLE; URINE;

ADULT; ANTIHYPERTENSIVE AGENTS; BELGIUM; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY DISEASE; DIABETES MELLITUS; ELECTROPHORESIS, CAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; MALE; MASS SPECTROMETRY; MIDDLE AGED; MORTALITY; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEOME; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SYSTOLE; URINALYSIS;

EID: 84940036300     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05296     Document Type: Article

References (39)

1. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, Dominiczak AF., Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 2009 28 703 724. doi: 10.1002/mas.20205
2. Zürbig P, Jerums G, Hovind P, Macisaac RJ, Mischak H, Nielsen SE, Panagiotopoulos S, Persson F, Rossing P., Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012 61 3304 3313. doi: 10.2337/db12-0348
3. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF., Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006 7 230 240. doi: 10.1016/S1470-2045(06)70584-8
4. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E, Bettendorf O, Wulfing C, Semjonow A., Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005 26 2797 2808. doi: 10.1002/elps.200400208
5. von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, Vanholder RC, Dominiczak AF, Chen YC, Mischak H, Bode C, Peter K., Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 2009 8 335 345. doi: 10.1021/pr800615t
6. Kuznetsova T, Mischak H, Mullen W, Staessen JA., Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J 2012 33 2342 2350. doi: 10.1093/eurheartj/ehs185
7. Zhang Z, Staessen JA, Thijs L, Gu Y, Liu Y, Jacobs L, Koeck T, Zürbig P, Mischak H, Kuznetsova T., Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population. Int J Cardiol 2014 176 158 165. doi: 10.1016/j.ijcard.2014.07.014
8. Gu YM, Thijs L, Liu YP, Zhang Z, Jacobs L, Koeck T, Zürbig P, Lichtinghagen R, Brand K, Kuznetsova T, Olivi L, Verhamme P, Delles C, Mischak H, Staessen JA., The urinary proteome as correlate and predictor of renal function in a population study. Nephrol Dial Transplant 2014 29 2260 2268. doi: 10.1093/ndt/gfu234
9. Li Y, Zagato L, Kuznetsova T, Tripodi G, Zerbini G, Richart T, Thijs L, Manunta P, Wang JG, Bianchi G, Staessen JA., Angiotensin-converting enzyme I/D and alpha-Adducin Gly460Trp polymorphisms: from angiotensin-converting enzyme activity to cardiovascular outcome. Hypertension 2007 49 1291 1297. doi: 10.1161/HYPERTENSIONAHA.106.085498
10. Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhäger WH, Herrmann SM, Fagard R, Tizzoni L, Bianchi G., Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens 2001 19 1349 1358
11. Mischak H, Vlahou A, Ioannidis JP., Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem 2013 46 432 443
12. Staessen J, Bulpitt CJ, Fagard R, Joossens JV, Lijnen P, Amery A., Familial aggregation of blood pressure, anthropometric characteristics and urinary excretion of sodium and potassium-A population study in two Belgian towns. J Chronic Dis 1985 38 397 407
13. Kuznetsova T, Staessen JA, Kawecka-Jaszcz K, Babeanu S, Casiglia E, Filipovsky J, Nachev C, Nikitin Y, Peleskã J, O'Brien E., Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Press Monit 2002 7 215 224
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 150 604 612
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabet Care 2003 26 suppl 1 S5 S20
16. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008 27 157 172; discussion 207. doi: 10.1002/sim.2929
17. Kuznetsova T, Thijs L, Knez J, Herbots L, Zhang Z, Staessen JA., Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Heart Assoc 2014 3 e000789. doi: 10.1161/JAHA.114.000789
18. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ., Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003 289 194 202
19. Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, Field E, Schatz CR, Estock MA, Ahmed N, Anderson NG, Steiner S., Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004 4 1159 1174. doi: 10.1002/pmic.200300661
20. Burlew BS, Weber KT., Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002 27 92 98
21. Kadler KE, Hill A, Canty-Laird EG., Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol 2008 20 495 501. doi: 10.1016/j.ceb.2008.06.008
22. Llorian M, Beullens M, Andrés I, Ortiz JM, Bollen M., SIPP1, a novel pre-mRNA splicing factor and interactor of protein phosphatase-1. Biochem J 2004 378 Pt 1 229 238. doi: 10.1042/BJ20030950
23. Neumann J., Altered phosphatase activity in heart failure, influence on Ca2+ movement. Basic Res Cardiol 2002 97 (suppl 1) I91 I95
24. Dakna M, Harris K, Kalousis A, Carpentier S, Kolch W, Schanstra JP, Haubitz M, Vlahou A, Mischak H, Girolami M., Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 2010 11 594. doi: 10.1186/1471-2105-11-594
25. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 360 1903 1913
26. Li Y, Wei FF, Thijs L, International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation 2014 130 466 474. doi: 10.1161/CIRCULATIONAHA.113.004876
27. Gordon T, Sorlie P, Kannel WB., Problems in the assessment of blood pressure: the Framingham Study. Int J Epidemiol 1976 5 327 334
28. Prentice RL, Shimizu Y, Lin CH, Peterson AV, Kato H, Mason MW, Szatrowski TP., Serial blood pressure measurements and cardiovascular disease in a Japanese cohort. Am J Epidemiol 1982 116 1 28
29. Harris T, Cook EF, Kannel W, Schatzkin A, Goldman L., Blood pressure experience and risk of cardiovascular disease in the elderly. Hypertension 1985 7 118 124
30. Pekkanen J, Tervahauta M, Nissinen A, Karvonen MJ., Does the predictive value of baseline coronary risk factors change over a 30-year follow-up? Cardiology 1993 82 181 190
31. Welin L, Eriksson H, Larsson B, Svärdsudd K, Wilhelmsen L, Tibblin G., Risk factors for coronary heart disease during 25 years of follow-up. The study of men born in 1913. Cardiology 1993 82 223 228
32. Wannamethee SG, Shaper AG, Whincup PH, Walker M., Role of risk factors for major coronary heart disease events with increasing length of follow up. Heart 1999 81 374 379
33. McCarron P, Smith GD, Okasha M, McEwen J., Blood pressure in young adulthood and mortality from cardiovascular disease. Lancet 2000 355 1430 1431. doi: 10.1016/S0140-6736(00)02146-2
34. Vasan RS, Massaro JM, Wilson PW, Seshadri S, Wolf PA, Levy D, D'Agostino RB, Framingham Heart Study Antecedent blood pressure and risk of cardiovascular disease: the Framingham Heart Study. Circulation 2002 105 48 53
35. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000 283 1967 1975
36. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288 2981 2997
37. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Diuretic versus α-blocker as first step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003 42 239 246
38. van Wijk DF, Boekholdt SM, Wareham NJ, Ahmadi-Abhari S, Kastelein JJ, Stroes ES, Khaw KT., C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study. Arterioscler Thromb Vasc Biol 2013 33 2888 2894. doi: 10.1161/ATVBAHA.113.301736
39. Xanthakis V, Enserro DM, Murabito JM, Polak JF, Wollert KC, Januzzi JL, Wang TJ, Tofler G, Vasan RS., Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study. Circulation 2014 130 1676 1683. doi: 10.1161/CIRCULATIONAHA.114.009273.